Mucosis BV
This article was originally published in Start Up
Executive Summary
To date, the most common route of vaccination has been as an intramuscular injection, which raises a systemic immune response to the selected pathogen. Mucosal vaccines can trigger both a local and systemic immune response, limiting pathogen invasion at the point of entry. Mucosis BV is developing nasally and orally delivered mucosal vaccines to prevent and treat infectious and other diseases. Its technology is based on particles derived from inactivated Lactococcus lactis bacteria, which are used in cheese and buttermilk production and so are safe for human use.
You may also be interested in...
Start-Up Previews (12/2010)
A preview of the emerging health ncompanies profiled in the current issue of Start-Up. This month's profile group, "Noninvasive Body Contouring Begins To Take Shape," features profiles of EndyMed, Slender Medical and Zeltiq. Plus these Start-Ups Across Health Care: Auxogyn, Mucosis, NuVue Therapeutics, Taiga Biotechnologies and ZetrOZ.
Gadeta BV: Using T-Cells To Target Metabolic Dysregulation In Cancer
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.